NCT02646020 - Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment | Biotech Hunter

Enrollment

138

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

October 1, 2020

Study Completion Date

December 1, 2020

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Aprepitant

aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)

DRUG

Desloratadine

Desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)

DRUG

Placebo of aprepitant

Placebo of aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)

DRUG

Placebo of desloratadine

Placebo of desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)

Trial Locations (1)

Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER